LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.

ANTIOXIDANTS AND OTHER NUTRIENTS DO NOT INTERFERE WITH CHEMOTHERAPY OR RADIATION, AND CAN INCREASE KILL, DECREASE SIDE EFFECTS, AND INCREASE SURVIVAL

HUMAN STUDIES
Fifty human studies, involving 8,521 patients, 5,081 of whom were given food supplement nutrients, have consistently shown that non-prescription antioxidants and other nutrients: Do not interfere with cancer therapeutic modalities; Can enhance cancer therapy killing capabilities; Decrease cancer therapy side effects; Protect normal tissues from cancer therapy, and Prolong lifespan in 15 studies for 3,738 patients